Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE-TOGETHER Trial in Long COVID-19 Syndrome
NCT06128967Phase 3Completed
- Sponsor
- CardResearch
- Start
- Oct 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluvoxamine, liquid metformin (Aspargo Labs) in coronavirus disease 2019 (COVID-19), myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS), sponsored by CardResearch. Started Oct 2023; status: completed.
02
Drugs
fluvoxamineliquid metformin (Aspargo Labs)
03
Conditions
coronavirus disease 2019 (COVID-19)myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT06128967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128967.